Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes

被引：19

作者：

Senda, C

Yamaura, Y

Kobayashi, K

Fujii, H

Minami, H

Sasaki, Y

Igarashi, T

Chiba, K

机构：

[1] Chiba Univ, Fac Pharmaceut Sci, Biochem Pharmacol & Biotoxicol Lab, Inage Ku, Chiba 2638522, Japan

[2] Natl Canc Ctr Hosp E, Chiba, Japan

[3] Nippon Boehringer Ingelheim Co, Kawanishi Pharma Res Inst, Dept Drug Metab & Pharmacokinet, Kawanishi, Hyogo, Japan

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2001年 / 52卷 / 01期

关键词：

CYP2D6*10; human liver microsomes; mexiletine;

D O I：

10.1046/j.0306-5251.2001.01411.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aims To study the influence of CYP2D6*10 on the formation of p-hydroxymexiletine (PHM) and hydroxymethylmexiletine (HMM) using microsomes from human liver of known genotypes. Methods Microsomes from human livers of genotype CYP2D6*1/*1 (n = 5), *1/*10 (n = 6) and *10/*10 (n = 6) were used in this study. The formation of PHM and HMM was determined by high-performance liquid chromatography. Results The formation rates of PHM and HMM were decreased by more than 50% and 85% in CYP2D6*1/*10 and *10/*10 microsomes, respectively, compared with *1/*1 microsomes. Concl(u)sions The metabolism of mexiletine to form PHM and HMM appears to be impaired to a significant extent in human liver microsomes from hetero- and homozygotes of CYP2D6*10.

引用

页码：100 / 103

页数：4

共 50 条

[1] Timolol metabolism in human liver microsomes is mediated principally by CYP2D6
Volotinen, Marjo
Turpeinen, Miia
Tolonen, Ari
Uusitalo, Jouko
Maenpaa, Jukka
Pelkonen, Olavi
DRUG METABOLISM AND DISPOSITION, 2007, 35 (07) : 1135 - 1141
[2] Metabolism of pimozide by CYP3A and CYP2D6 in human liver microsomes.
Flockhart, DA
Richard, E
Soukova, N
Kerbusch, T
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PIV65 - PIV65
[3] Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes
Lalovic, B
Phillips, B
Risler, LL
Howald, W
Shen, DD
DRUG METABOLISM AND DISPOSITION, 2004, 32 (04) : 447 - 454
[4] CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes
Hutchinson, MR
Menelaou, A
Foster, DJR
Coller, JK
Somogyi, AA
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (03) : 287 - 297
[5] INVOLVEMENT OF CYP2D6 IN OXIDATIVE-METABOLISM OF CINNARIZINE AND FLUNARIZINE IN HUMAN LIVER-MICROSOMES
NARIMATSU, S
KARIYA, S
ISOZAKI, S
OHMORI, S
KITADA, M
HOSOKAWA, S
MASUBUCHI, Y
SUZUKI, T
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 193 (03) : 1262 - 1268
[6] Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2
Haritos, VS
Ching, MS
Ghabrial, H
Gross, AS
Taavitsainen, P
Pelkonen, O
Battaglia, SE
Smallwood, RA
Ahokas, JT
PHARMACOGENETICS, 1998, 8 (05): : 423 - 432
[7] Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients
Roh, HK
Kim, CE
Chung, WG
Park, CS
Svensson, JO
Bertilsson, L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (09) : 671 - 675
[8] Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients
Hyung-Keun Roh
Chul-Eung Kim
Woon-Gye Chung
Chang-Shin Park
Jan-Olof Svensson
Leif Bertilsson
European Journal of Clinical Pharmacology, 2001, 57 : 671 - 675
[9] Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone
Cho, Chang-Keun
Byeon, Ji-Young
Kang, Pureum
Park, Jung-In
Jang, Choon-Gon
Lee, Seok-Yong
Choi, Chang-Ik
Bae, Jung-Woo
Lee, Yun Jeong
ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (01) : 59 - 64
[10] Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone
Chang‑Keun Cho
Ji-Young Byeon
Pureum Kang
Jung-In Park
Choon-Gon Jang
Seok-Yong Lee
Chang-Ik Choi
Jung‑Woo Bae
Yun Jeong Lee
Archives of Pharmacal Research, 2023, 46 : 59 - 64

← 1 2 3 4 5 →